In contrast to previous studies that predominantly utilized select MA peptides in the context of specific HLA alleles and the flow cytometry-based multimer approach, we opted to utilize extensive peptide pools that systematically covered the entire amino acid sequence of the melanoma antigens; tyrosinase, MAGE-A3, Melan-A/Mart-1, gp100 and NY-ESO-1. This evidence concerns the gene MAGEA3 and melanoma.